Back to search results

Kinisoquin™ for Preventing Blood Clots in Pancreatic Cancer

This study is looking at whether Kinisoquin™, a capsule containing vitamin C and B3, can help prevent blood clots (thromboembolic events) in people with pancreatic cancer that has spread (metastatic) or is locally advanced. About one-third of pancreatic cancer patients experience these clots, especially in the first three months of chemotherapy. You might be able to join if you have confirmed metastatic or locally advanced pancreatic cancer and are starting your first chemotherapy treatment within 45 days. The main goal is to see how well Kinisoquin™ works compared to a placebo (an inactive pill) over 16 weeks. The current status of this study is unclear.

Study design
This is a Phase 3, randomized, placebo-controlled, double-blinded study aiming to enroll 480 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The effectiveness of Kinisoquin™ is measured at 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06861088

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Recruiting
PHASE3Ages 18+InterventionalPrevention
Quercis Pharma AG
~480 participants
Updated 2026-02-02 on ClinicalTrials.gov
What's tested:Kinisoquin™Placebo

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effectiveness of Kinisoquin™
Measured over 16 weeks
+1 more outcome measured

Conditions

Venous Thromboembolism
Metastatic Pancreatic Cancer
Locally Advanced Pancreatic Adenocarcinoma

Explore related trials

Pancreatic Adenocarcinoma

NCT06861088

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusettsno site contact published

    Recruiting

  • Clavis Medical, LLC

    Miami Lakes, Floridano site contact published

    Recruiting

  • Ventura Clinical Trials

    Ventura, Californiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Mukesh Kumar, PhD
[email protected]
240-750-4893
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Platelet count ≥ 100,000/mcL.
Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5x institutional upper limit of normal (ULN).
Total bilirubin ≤ 3x ULN without liver metastases and \< 5x ULN in presence of liver metastases.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x ULN without liver metastases and \< 5x ULN in the presence of liver metastases
Estimated creatinine clearance (CrCl \> 30 mL/min). 7. Willingness of women of child-bearing potential and men to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until at least 4 weeks after study completion. 8. Ability to understand and the willingness to sign a written informed consent document.

What this trial measures

  • Effectiveness of Kinisoquin™16 weeks

    The time to the first positively adjudicated thromboembolic event (TE) over 16 weeks of treatment in patients treated with Kinisoquin™ compared with placebo.

  • Effectiveness of Kinisoquin™16 weeks

    The time to the first positively adjudicated proximal or distal lower extremity DVT, any pulmonary embolism, fatal pulmonary embolism diagnosed on autopsy, catheter-related thrombosis, visceral thrombosis or arterial thrombosis. Events will be classified as incidental or symptomatic: incidental TE will be so classified if the imaging was ordered primarily for staging or re-staging or conducted for reasons other than identification of a thrombosis as compared to the placebo.